Cediranib
- Generic Name
- Cediranib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H27FN4O3
- CAS Number
- 288383-20-0
- Unique Ingredient Identifier
- NQU9IPY4K9
- Background
The novel indole-ether quinazoline Cediranib is a highly potent (IC < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.
- Indication
For the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 9
- Registration Number
- NCT02899728
- Locations
- ๐บ๐ธ
Los Angeles County-USC Medical Center, Los Angeles, California, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธMayo Clinic in Florida, Jacksonville, Florida, United States
Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer
- Conditions
- Castration-Resistant Prostate CarcinomaMetastatic Prostate Adenocarcinoma With Neuroendocrine DifferentiationStage IV Prostate Adenocarcinoma AJCC v7Metastatic Prostate CarcinomaProstate Adenocarcinoma With Neuroendocrine DifferentiationAdvanced Prostate Adenocarcinoma With Neuroendocrine Differentiation
- Interventions
- First Posted Date
- 2016-09-09
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 90
- Registration Number
- NCT02893917
- Locations
- ๐บ๐ธ
Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธWayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-08-04
- Last Posted Date
- 2022-02-22
- Lead Sponsor
- The Christie NHS Foundation Trust
- Target Recruit Count
- 28
- Registration Number
- NCT02855697
- Locations
- ๐ฌ๐ง
The Christie NHS Foundation Trust, Manchester, United Kingdom
A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer
- First Posted Date
- 2016-02-12
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 34
- Registration Number
- NCT02681237
- Locations
- ๐จ๐ฆ
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
- Conditions
- Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Serous AdenocarcinomaFallopian Tube Transitional Cell CarcinomaFallopian Tube Undifferentiated CarcinomaOvarian Clear Cell AdenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Seromucinous CarcinomaOvarian Serous AdenocarcinomaOvarian Transitional Cell Carcinoma
- Interventions
- First Posted Date
- 2015-07-20
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 587
- Registration Number
- NCT02502266
- Locations
- ๐บ๐ธ
West Penn Hospital, Pittsburgh, Pennsylvania, United States
๐บ๐ธPacific Gynecology Specialists, Seattle, Washington, United States
๐บ๐ธWomen's Cancer Center of Seattle, Seattle, Washington, United States
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
- Conditions
- Interventions
- First Posted Date
- 2015-06-29
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 384
- Registration Number
- NCT02484404
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib
- First Posted Date
- 2015-01-16
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 4
- Registration Number
- NCT02340611
- Locations
- ๐จ๐ฆ
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 34
- Registration Number
- NCT01391962
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 19
- Registration Number
- NCT01364051
- Locations
- ๐บ๐ธ
Mayo Clinic in Florida, Jacksonville, Florida, United States
๐บ๐ธMayo Clinic in Rochester, Rochester, Minnesota, United States
A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)
- First Posted Date
- 2011-04-18
- Last Posted Date
- 2019-01-24
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 36
- Registration Number
- NCT01337401
- Locations
- ๐ฆ๐บ
Princess Alexandra Hospital, Brisbane, Australia
๐ฆ๐บRoyal Prince Alfred Hospital, Sydney, Australia
๐ช๐ธHospital Puerta de Hierro, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.